Grants for For profit organizations other than small businesses - Federal

The "Research on Autism Spectrum Disorders" grant aims to fund projects that explore the causes, prevalence, diagnosis, and best service delivery methods for Autism Spectrum Disorders, with a focus on small, well-defined projects that can be completed within two years using limited resources.

NRCS is announcing the availability of Conservation Innovation Grants (CIG) State Program funding to stimulate the development and adoption of innovative conservation approaches and technologies. Applications are accepted from eligible entities (Section C) for projects carried out in the state of New York A total of up to $500,000 is available for the New York CIG competition in FY 2024. All non-Foreign, non-federal entities (NFE) and individuals are invited to apply, with the sole exception of federal agencies. Projects may be between one and three years in duration. The maximum award amount for a single award in FY 2024 is $500,000. For new users of Grants.gov, see Section D. of the full Notice of Funding Opportunity for information about steps required before submitting an application via Grants.gov. Completing all steps required to start an application can take a significant amount of time, plan accordingly. Key Dates Applicants must submit their applications via Grants.gov by 11:59 pm Eastern Time on May 10, 2024. [AF1] For technical issues with Grants.gov, contact Grants.gov Applicant Support at 1-800-518-4726 or [email protected]. Awarding agency staff cannot support applicants regarding Grants.gov accounts. For inquiries specific to the content of the NFO requirements, contact the federal awarding agency contact (section G of this NFO). Please limit questions to those regarding specific information contained in this NFO (such as dates, page numbers, clarification of discrepancies, etc.). Questions related to eligibility, or the merits of a specific proposal will not be addressed. Applicants are encouraged to visit the New York State CIG website to learn more about the CIG program. The agency anticipates making selections by June 10, 2024 and expects to execute awards by July 26, 2024. These dates are estimates and are subject to change.

The FY24 DMDRP IDA promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.New Investigators: The FY24 DMDRP IDA mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent) or applications from established investigators new to DMD research.The New Investigator Early Stage category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators.The New Investigator Transitioning category is designed to allow investigators in an area other than muscular dystrophy, at or above the level of Assistant Professor, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator Early Stage category or New Investigator Transitioning category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PIs expertise to best address the research question. All applicants for the New Investigator categories must meet the specific eligibility criteria described in Section II.C, Eligibility Information.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required. Preliminary data may include unpublished results from the laboratory of the PI, research team or collaborators named on the application.Key elements of this award are as follows:Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward improving outcomes for individuals with DMD.It is the responsibility of the PI to clearly and explicitly articulate the projects innovation and its potential impact on DMD. The projects impact to both DMD research and to individuals with DMD should be articulated, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack innovation and high potential impact do not meet the intent of the IDA.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.

This funding opportunity supports collaborative research projects aimed at understanding and treating infectious and immune-related diseases, open to a wide range of organizations including universities, nonprofits, and government entities.

This funding opportunity provides financial support to designated regional consortia that include educational institutions, government entities, and industry partners to advance critical technologies and foster economic growth in their areas.

YSEALI (yseali.state.gov) is the U.S. governments signature initiative to engage emerging leaders in Southeast Asia. The program aims to create a network of young Southeast Asian leaders who work across national borders to solve common problems. Through a variety of programs and engagements, YSEALI seeks to build the leadership capabilities of youth in the region, strengthen ties between the United States and Southeast Asia, and nurture a community of leaders who work across borders to solve shared issues. YSEALI is open to young leaders ages 18 to 35 who are both citizens and residents of the Association of Southeast Asian Nations (ASEAN) member countries (Brunei, Burma, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, and Vietnam) or Timor-Leste. Responding to priorities from youth in the ASEAN region, YSEALI programs focus on four themes (i.e., Civic Engagement, Economic Empowerment and Social Entrepreneurship, Education and Environmental Issues). The 2025 YSEALI WLA: InnovateHER will advance all of the YSEALI themes and the U.S. Mission to ASEANs strategic goals: Sub-objective 3.2.1. ASEAN recognizes the contribution of women in the economic recovery of the region and strives to promote DEIA principles across its economic community pillar. Sub-objective 3.2.2. The United States creates a program to promote the role of women across ASEAN in contributing to peace and security across the region. The 2025 YSEALI WLA: InnovatHER will be designed for 50 to 60 female participants who have professional experience working in the tech industry. Possible fields include artificial intelligence technology, clean energy, cybersecurity, software development, medical technology research, and tech start-up incubators. The participants, age 20 to 35, must represent all 10 of the Association of Southeast Asian Nations (ASEAN) member states and Timor-Leste. The Academy will have pre-workshop virtual activities and an in-person four-day or five-day workshop located in Southeast Asia. The purpose of the pre-workshop and workshop activities will be to: (1) create a network of Southeast Asian women making advances in technology who will design future activities and workshops for women in the YSEALI network; (2) explore how technological advancements, including artificial intelligence, could improve the daily lives of women; (3) discuss political and governmental policies that are affecting womens access to the digital economy and technological advancements; (4) develop general leadership skills, including self-awareness of personal professional strengths. FULL NOFO is on the U.S. Mission to ASEAN website here.

The DoD Reconstructive Transplant, Idea Discovery Award is a funding opportunity aimed at supporting innovative, high-risk/high-reward research projects related to reconstructive transplant, with a focus on generating robust data, addressing military health care needs, advancing women's health research, and adhering to rigorous experimental design, with a total budget not exceeding $500,000.

This funding opportunity supports the development of a national data resource center to improve research on childhood cancers and congenital anomalies, encouraging collaboration among a wide range of organizations and researchers.

Agency Description: The Advanced Research Projects Agency Energy (ARPA-E), an organization within the Department of Energy (DOE), is chartered by Congress in the America COMPETES Act of 2007 (P.L. 110-69), as amended by the America COMPETES Reauthorization Act of 2010 (P.L. 111-358), as further amended by the Energy Act of 2020 (P.L. 116-260): (A) to enhance the economic and energy security of the United States through the development of energy technologies that (i) reduce imports of energy from foreign sources; (ii) reduce energy-related emissions, including greenhouse gases; (iii) improve the energy efficiency of all economic sectors; (iv) provide transformative solutions to improve the management, clean-up, and disposal of radioactive waste and spent nuclear fuel; and (v) improve the resilience, reliability, and security of infrastructure to produce, deliver, and store energy; and (B) to ensure that the United States maintains a technological lead in developing and deploying advanced energy technologies. ARPA-E issues this Funding Opportunity Announcement (FOA) under its authorizing statute codified at 42 U.S.C. 16538. The FOA and any cooperative agreements or grants made under this FOA are subject to 2 C.F.R. Part 200 as supplemented by 2 C.F.R. Part 910. ARPA-E funds research on, and the development of, transformative science and technology solutions to address the energy and environmental missions of the Department. The agency focuses on technologies that can be meaningfully advanced with a modest investment over a defined period of time in order to catalyze the translation from scientific discovery to early-stage technology. For the latest news and information about ARPA-E, its programs and the research projects currently supported, see: http://arpa-e.energy.gov/. ARPA-E funds transformational research. Existing energy technologies generally progress on established learning curves where refinements to a technology and the economies of scale that accrue as manufacturing and distribution develop drive improvements to the cost/performance metric in a gradual fashion. This continual improvement of a technology is important to its increased commercial deployment and is appropriately the focus of the private sector or the applied technology offices within DOE. In contrast, ARPA-E supports transformative research that has the potential to create fundamentally new learning curves. ARPA-E technology projects typically start with cost/performance estimates well above the level of an incumbent technology. Given the high risk inherent in these projects, many will fail to progress, but some may succeed in generating a new learning curve with a projected cost/performance metric that is significantly better than that of the incumbent technology. ARPA-E funds technology with the potential to be disruptive in the marketplace. The mere creation of a new learning curve does not ensure market penetration. Rather, the ultimate value of a technology is determined by the marketplace, and impactful technologies ultimately become disruptive that is, they are widely adopted and displace existing technologies from the marketplace or create entirely new markets. ARPA-E understands that definitive proof of market disruption takes time, particularly for energy technologies. Therefore, ARPA-E funds the development of technologies that, if technically successful, have clear disruptive potential, e.g., by demonstrating capability for manufacturing at competitive cost and deployment at scale. ARPA-E funds applied research and development. The Office of Management and Budget defines applied research as an original investigation undertaken in order to acquire new knowledgedirected primarily towards a specific practical aim or objective and defines experimental development as creative and systematic work, drawing on knowledge gained from research and practical experience, which is directed at producing new products or processes or improving existing products or processes. Applicants interested in receiving financial assistance for basic research (defined by the Office of Management and Budget as experimental or theoretical work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts) should contact the DOEs Office of Science (http://science.energy.gov/). Office of Science national scientific user facilities (http://science.energy.gov/user-facilities/) are open to all researchers, including ARPA-E Applicants and awardees. These facilities provide advanced tools of modern science including accelerators, colliders, supercomputers, light sources and neutron sources, as well as facilities for studying the nanoworld, the environment, and the atmosphere. Projects focused on early-stage R for the improvement of technology along defined roadmaps may be more appropriate for support through the DOE applied energy offices including: the Office of Energy Efficiency and Renewable Energy (http://www.eere.energy.gov/), the Office of Fossil Energy and Carbon Management (https://www.energy.gov/fecm/office-fossil-energy-and-carbon-management), the Office of Nuclear Energy (http://www.energy.gov/ne/office-nuclear-energy), and the Office of Electricity (https://www.energy.gov/oe/office-electricity). FOA Description: According to the U.S. Environmental Protection Agency (EPA), a circular economy refers to an economy that uses a systems-focused approach and involves industrial processes and economic activities that are restorative or regenerative by design, enables resources used in such processes and activities to maintain their highest value for as long as possible, and aims for the elimination of waste through the superior design of materials, products, and systems. Further, a circular economy reduces material use, redesigns materials, products, and services to be less resource intensive, and recaptures waste as a resource to manufacture new materials and products. Successfully achieving a circular economy requires implementing the above principles to the supply chains of numerous products. Specifically, creating a circular EV battery supply chain focuses on optimizing the full vehicle life cycle. Thus, the emphasis must shift from production and sales within an ownership model to a model focusing on customers mobility needs and access in the form of leasing, as it exists today, vehicle-on-demand (e.g., Zipcar), and mobility-on-demand (e.g., robotaxis). These different business models may coexist but will require increasing collaboration and transparency among different actors, while costs and revenues will be distributed across the supply chain. A circular supply chain offers new revenue streams and business opportunities by providing services to maximize EVs lifetime performance through: Enhancing regular predictive maintenance; Repairing and remanufacturing of battery modules and packs; Improving the reuse and recovery of EOL parts and materials; and Minimizing carbon footprint and maximizing resource efficiency. A circular supply chain also offers opportunities to reduce production and operating costs by: Improving the quality and stability of critical minerals supply chains through cell regeneration, reuse, and recycling; Facilitating rework, reuse, repair, and remanufacture of batteries through modular designs, reversible manufacturing materials and methods; and Reducing asset costs per unit amount of energy delivered owing to the retention of the embedded manufacturing value of batteries, their prolonged lifetime, and the extended use of EVs. The overarching goal of the CIRCULAR program is to successfully translate the above definition of a circular economy to the domestic EV battery supply chain by supporting the development of innovative solutions that can overcome both the technological and economic barriers to broad commercial adoption. CIRCULAR acknowledges that simultaneous advancements in multiple technological domains may be required to accomplish this ambitious objective. Therefore, the program is intentionally structured into four technology development categories designed to converge towards the creation of a domestic circular supply chain for EV batteries. The CIRCULAR program recognizes that conventional recycling is not the only, nor primary, pathway to closing the supply chain loop. Therefore, the primary objective of this program is to catalyze the creation of a circular EV battery supply chain in North America. The program will support the development and deployment of foundational technologies capable of maintaining materials and products in circulation at their highest level of performance and safety for as long as possible. Achieving this goal will directly impact ARPA-E mission areas as follows: Decrease Energy-Related Imports: The CIRCULAR program aims to reduce the import of critical battery materials, cells, packs, and EVs by establishing new supply chain loops within the U.S. Currently, individual steps in the battery supply chain (mining, material processing, cell component assembly, battery cell manufacturing, and recycling) are concentrated mostly outside of the U.S. Reduce Emissions: The CIRCULAR program aims to decrease the domestic energy burden and carbon footprint of the EV battery supply chain by extending the service life of battery cells and packs and by maintaining manufacturing value to the greatest extent possible through regeneration, repair, reuse, and remanufacture. The program will also reduce emissions associated with battery recycling by minimizing the amount of waste and by recycling only pack components that have reached their EOL. Improve Energy Efficiency: The CIRCULAR program aims to minimize energy and material consumption within the battery supply chain and to exploit opportunities to improve energy efficiency through innovative battery design, material regeneration, and/or manufacturing strategies. According to the U.S. Environmental Protection Agency (EPA), a circular economy refers to an economy that uses a systems-focused approach and involves industrial processes and economic activities that are restorative or regenerative by design, enables resources used in such processes and activities to maintain their highest value for as long as possible, and aims for the elimination of waste through the superior design of materials, products, and systems. Further, a circular economy reduces material use, redesigns materials, products, and services to be less resource intensive, and recaptures waste as a resource to manufacture new materials and products. Successfully achieving a circular economy requires implementing the above principles to the supply chains of numerous products. Specifically, creating a circular EV battery supply chain focuses on optimizing the full vehicle life cycle. Thus, the emphasis must shift from production and sales within an ownership model to a model focusing on customers mobility needs and access in the form of leasing, as it exists today, vehicle-on-demand (e.g., Zipcar), and mobility-on-demand (e.g., robotaxis). These different business models may coexist but will require increasing collaboration and transparency among different actors, while costs and revenues will be distributed across the supply chain. A circular supply chain offers new revenue streams and business opportunities22 by providing services to maximize EVs lifetime performance through: Enhancing regular predictive maintenance; Repairing and remanufacturing of battery modules and packs; Improving the reuse and recovery of EOL parts and materials; and Minimizing carbon footprint and maximizing resource efficiency. A circular supply chain also offers opportunities to reduce production and operating costs by: Improving the quality and stability of critical minerals supply chains through cell regeneration, reuse, and recycling; Facilitating rework, reuse, repair, and remanufacture of batteries through modular designs, reversible manufacturing materials and methods; and Reducing asset costs per unit amount of energy delivered owing to the retention of the embedded manufacturing value of batteries, their prolonged lifetime, and the extended use of EVs. To view the FOA in its entirety, please visit https://arpa-e-foa.energy.gov.

In FY23, the OCRP established a new academy, the Ovarian Cancer Clinical Trial Academy (OCCTA), which will focus on clinical trial research in ovarian cancer. The intent of the OCCTA is to enhance knowledge within next generation of Early-Career Investigators (ECIs) in clinical trial research and to produce effective treatments and cures for ovarian cancer. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer. The OCCTA strives to develop successful, highly productive ovarian cancer clinical trialists in a collaborative research and career development environment, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials.

This funding opportunity supports researchers in atmospheric science to utilize satellite data for advancing the understanding of precipitation, cloud dynamics, and related processes, particularly through the integration of legacy and current satellite missions.

This program provides funding to a wide range of organizations, including nonprofits, universities, and businesses, to develop innovative solutions for producing personalized genetic medicines quickly and efficiently, improving patient access across the United States.

This funding opportunity provides financial support for research projects that enhance data collection and analysis related to breast cancer, specifically targeting gaps in existing clinical studies and involving consumer advocates in the research process.

This funding opportunity supports projects that encourage low-income individuals to buy more fruits and vegetables by providing financial incentives through authorized retailers.

The "Puerto Rico Energy Resilience Fund: Resilient Communities Program" grant aims to use $1B in funding to enhance Puerto Rico's energy resilience and clean energy economy, particularly focusing on mitigating power outage impacts on low-income residents, ensuring energy reliability for healthcare services in disadvantaged communities, and supporting the growth of the clean energy workforce, through the installation of solar PV and battery storage in subsidized multi-family properties and community healthcare facilities.

The Department of States Office to Monitor and Combat Trafficking in Persons (TIP Office) is pleased to invite organizations to submit proposals to provide technical assistance focused on establishing survivor leadership and partnership structures in support of its global Training and Technical Assistance (T) Program. The Department of State’s Office to Monitor and Combat Trafficking in Persons (TIP Office) announces an open competition for projects to provide technical assistance focused on establishing survivor1 leadership and partnership structures 1 For simplicity and consistency, the terms “survivor” and “survivor leader” are used throughout this document. While some individuals who have experienced trafficking choose to embrace the title “survivor,” others do not. Terminology regarding human trafficking varies based on a country’s respective laws and language(s). The word “survivor” is not generally defined by law, nor is it in support of its global Training and Technical Assistance (T&TA) Program. The TIP Office manages foreign assistance programs dedicated to combating human trafficking outside of the United States. The TIP Office awards grants to combat all forms of human trafficking—sex trafficking, child sex trafficking, forced labor, domestic servitude, forced child labor, and the unlawful recruitment and use of child soldiers. The Department of State’s annual Trafficking in Persons Report (TIP Report) provides a diagnostic assessment of the efforts of governments to combat human trafficking and shapes our foreign assistance priorities. More information is available at: https://www.state.gov/international-programs-officeto-monitor-and-combat-trafficking-in-persons/. The TIP Office’s Training and Technical Assistance (T&TA) program aims to increase government and/or civil society capacity to combat human trafficking. T&TA is most appropriate for addressing specific knowledge or other capacity gaps through targeted, short-term interventions. The TIP Office can provide training and/or technical assistance on topics spanning all 4Ps – Prevention, Protection, Prosecution, and Partnership. T&TA interventions are most often initiated by requests from U.S. Embassies abroad, or sometimes from our T&TA implementing partners. The TIP Office reviews requests for T&TA on a rolling basis throughout the year. Selected T&TA requests are then referred by the TIP Office to the relevant implementer, depending on the type of assistance requested, the implementer’s areas of universally used or accepted in the context of human trafficking. In some countries, “survivor” may refer to those who have experienced historical, collective, or cultural trauma. Within the United States, there are some widely used terms for individuals who have experienced human trafficking and subsequently decided to engage in anti-trafficking related work on a professional level. Individuals may prefer to be referred to as “survivor leaders,” “survivor advocates,” or “subject matter experts with lived experience of human trafficking.” Some may have other titles or prefer not to identify based on this experience at all. In recognizing individuals’ full life experiences, skill sets, and professional goals, it is important to always ask someone how they want to be identified. Policymakers and stakeholders should not assume that someone who identifies as a “survivor leader,” “survivor advocate,” or “expert with lived experience of human trafficking” should be referred to as such in a professional setting or that identification as a survivor leader makes it acceptable to inquire about someone’s personal experience with human trafficking. expertise, and funding availability. The timeline to complete T&TA activities will depend on a variety of factors such as strategic priorities and country contexts. The selected implementer should be able to create an intervention concept note and budget in response to the specific T&TA request before the intervention is approved for implementation. The selected implementer should also expect to work closely with TIP Office staff throughout the development and implementation of interventions and activities. T&TA interventions can be standalone or they can lay the groundwork for or complement other programing, but they do not take the place of longer, multiyear programs. Individual T&TA interventions can sometimes also be structured in phases, with each phase being subject to TIP Office approval. T&TA activities may be conducted in countries across all regions of the world, so the scope of T&TA implementers’ capabilities must be global. The selected applicant should be able to respond to unanticipated requests for assistance in any country and/or region, with few exceptions. Some examples of what past T&TA interventions have looked like include the following: • Review of and edits to draft legislation or implementing regulations on a 24-hour turnaround; • Development and adoption of Foreign Government National Action Plan over the course of five months from receipt of request to final adoption; • Targeted technical assistance on the process to accede to United Nations Convention Against Transnational Organized Crime (UNTOC) and the Palermo Protocol; • Rapid diagnostic needs assessment on anti-trafficking capacity gaps of specialized anti-trafficking practitioners conducted within 4 weeks of initial request, followed by the development and delivery of a tailored training curriculum; • Tailored trainings delivered to law enforcement, prosecutors, and judges on how to build a human trafficking case in a country with limited resources and low capacity; • Tailored trainings delivered to shelter staff to improve identification, screening, and assistance of victims of trafficking, as well as technical assistance to develop necessary tools, such as screening forms and risk assessments; • Creation and implementation of a training series curriculum tailored to psychological and legal service providers to victims of trafficking in urban and rural locations both virtually and in-person, delivered over the course of several months; • Regional training for law enforcement and prosecutors, tailoring the materials to for applicability across various participating countries in the region. While some T&TA activities can be conducted remotely, and the ability to provide some programming virtually is an asset to the T&TA Program and to the selected implementers, the majority of T&TA activities are conducted in-person. Because T&TA interventions can take place in settings where utilities, such as internet connectivity, are unreliable, the TIP Office will not be able to consider applications whose model of T&TA delivery is entirely remote.

The U.S. Department of States Bureau of Democracy, Human Rights, and Labor (DRL), in coordination with the Bureau of International Narcotic and Law Enforcement Affairs (INL), announces an open competition for organizations interested in submitting applications for a professional development program to strengthen the practical skills and resiliency of anticorruption actors to combat corruption more effectively in Central America.

This funding opportunity is designed to establish a center that will coordinate and manage data for collaborative research on rare diseases, supporting various research consortia and engaging stakeholders to improve diagnosis and treatment.

This program funds projects that improve the safety, efficiency, and reliability of intercity passenger and freight rail. The Consolidated Rail Infrastructure and Safety Improvements (CRISI) Program is authorized under 49 U.S.C. 22907. The purpose of the CRISI Program is to invest in a wide range of projects within the United States to improve railroad safety, efficiency, and reliability; mitigate congestion at both intercity passenger rail and freight rail chokepoints to support more efficient travel and goods movement; enhance multi-modal connections; and lead to new or substantially improved Intercity Passenger Rail Transportation corridors. This program invests in railroad infrastructure projects that improve safety, support economic vitality (including through opportunities for small businesses), create good-paying jobs with the free and fair choice to join a union, increase capacity and supply chain resilience, apply innovative technology, and explicitly address climate change, gender equity and racial equity. The purpose of this notice is to solicit applications for the competitive CRISI Program provided in Consolidated Appropriations Act, 2023, division L, title I, Public Law 117–328 (2023 Appropriation), Consolidated Appropriations Act, 2024, division F, title I, Public Law 118–42 (2024 Appropriation) and the 2023 and 2024 advance appropriation in the Infrastructure Investment and Jobs Act, division J, title II, Public Law 117–58 (2021).

This ISO seeks solution summaries and proposals for projects that fall within the general scope of the ARPA-H Scalable Solutions mission office. SSO expands what is technically possible by developing approaches that will leverage an interdisciplinary approach and collaborative networks to address challenges of geography, distribution, manufacturing, data and information, thereby improving health care access and affordability. In the United States, many communities and remote areas lack access to timely and quality health care, which leads to disparities in health outcomes for those populations. Bottlenecks during the manufacturing processes of products and health technologies also lead to delays and limited availability, preventing effective distribution of health care solutions to areas of need, especially in emergencies.ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. The following SSO interest areas categorize the ground-breaking solutions we seek to support:Scalable Technologies and Interventions: Approaches to improve affordability and equitable access to health care that are adaptable to various geographic, demographic, economic contexts and can be rapidly deployed at scale (e.g., drug-repurposing*, telemedicine, point-of-care diagnostics, and modular health care infrastructure). Tailored solutions for the pediatric population that provide parity in access to treatments and other health care interventions with the adult population and adapt to the pediatric patients changing physiology and developmental status over the course of years. Transformational approaches to reduce or eliminate health disparities, including tools and models for product design and care delivery that scale novel approaches in human factors and human-centered design to respond to full diversity of patients. Tools to enable the scaling of provider and institutional capabilities (e.g., school nurses and schools, walk-in clinics, homesteading care) to address unmet health care access needs and expand availability of critical services. Foundational capabilities to accelerate diagnoses and reduce the cost of treatments for rare diseases wherever patients are, without the need for specialized facilities or healthcare expertise.* Solution summaries and proposals that focus on testing drugs for effectiveness for other disease states or use cases, are unlikely to be funded unless including additional R, or providing gains in cost reduction, accessibility, and/or equity.Collaborative Distribution Networks: Methods for standardization, automation, and democratization of complex procedures 5 including, but not limited to, histopathology, rare disease diagnosis and treatment, and surgical interventions to ensure access and delivery to populations diverse in demographics, geographies, and resources at scale. Approaches to enhance delivery of effective healthcare solutions in rural or low resource settings, including but not limited to "last mile delivery, at-home monitoring, imaging, drug delivery, telehealth augmentation, and support for remote medical procedures with limited need for specialized training. Technologies to enable the deployment of critical healthcare resources rapidly, equitably, and securely at scale to the point of need in permissive and non-permissive (i.e., damaged infrastructure, cyber-denied) environments during a public health crisis or natural disaster. Solutions to scale education and training of critical healthcare resources for health care providers and patients to ensure information integrity to prevent negative impacts to resource use/uptake. Innovative information technology, data and analytic products and technologies to enable ordering, inventory management, situational awareness, allocation planning and demand forecasting of critical healthcare resources during a public health crisis or natural disaster.Biomanufacturing Innovations*: Innovative manufacturing technologies and approaches that reduce cost, shorten the timeline for production, advance domestic competitiveness and reduce supply chain risk of biologics, cellular and gene therapies, pharmaceuticals, medical devices and personal protective equipment. New approaches to support predictable, programable biological production of conventional and novel materials reliability at scale in a cost-effective sustainable manner. Novel solutions to reduce the reliance on specialized handling and cold chain management of pharmaceuticals and biologics. Scalable innovations to advance and strengthen biomanufacturing supply chain and resolve bottlenecks including:o Advances in production of active pharmaceutical ingredients, process consumables, and other critical materials (i.e., enzymes, cell lines, etc);o Novel biomanufacturing-related data products, technologies or models to integrate into supply chain situational awareness systems;o Alternative materials and new manufacturing capabilities for personal protective equipment; ando Improvement of capabilities sustainably re-shore manufacturing and utilize a broad array of readily accessible and cost-efficient feedstocks as part of strengthening the local and national industry base. Analytics and novel sensor systems to precisely manage bioproduction, real-time release assays, and predictive capabilities to inform tuning of biological chassis for efficient and effective scale-up of manufacturing to industrial scale.*ARPA-H is not interested in approaches that merely increase capacity reservation.Other high-quality submissions that propose revolutionary technologies that meet the goals of SSO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.